References
- Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25(6): 1593–617.
- Falasca GF. Metabolic diseases: Gout. Clin Dermatol 2006; 24: 498–508.
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004 March 11; 350(11): 1093–103.
- Jacobs CL, Stern PJ. An unusual case of gout in the wrist: The importance of monitoring medication dosage and interaction. A case report. Chiropr Osteopat [serial on the internet] 2007 October 9;15(16) [about 5 pages]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174925/pdf/1746-1340-15-16.pdf (Accessed 2009 Dec 03).
- Kirby BS, McTigue JC, Edwards NL. Pain management in gout. Curr Pain Headache Rep 2008 December; 12(6):418–22.
- Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60: 59–68.
- Gaffo AL, Saag KG. Management of hyperuricemia and gout in CKD. Am J Kidney Dis 2008; 52(5): 994–1009.
- Darmawan J, Lutalo SK. Gout and hyperuricaemia. Bailliére's Clin Rheumatol 1995 February; 9(1): 83–94.
- Cheng T, Lai H, Chiu C, Chen Y. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004; 26(3): 399–406.
- Ren K, Torres R. Role of interleukin-1 β during pain and inflammation. Brain Res Rev 2009; 60(1): 57–64.
- Hoffman HM, Yasothan U, Kirkpatrick P. Fresh from the pipeline: Rilonacept. Nat Rev Drug Discov 2008 May; 7: 385–6.
- Chen LX, Schumacher HR. Gout: Can we create and evidence-based systematic approach to diagnosis and management? Best Pract Res Clin Rheumatol 2006; 20(4): 673–84.
- Richardson RMA. Treatment of asymptomatic hyperuricemia: When do you have a good reason to provide therapy? Can Fam Physician 1991 February; 37: 459–63.
- Fujimori S. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia.] Nippon Rinsho 2008 Apr; 66(4): 729–35.
- Hinz B, Brune K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci. 2008 August; 29(8): 391–397.
- Del Favero A. Anti-inflammatory and antipyretic analgesics and drugs used in gout. In: Aronson JK, editor. Side effects of drugs. Elsevier; 2008; 125–36.
- Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial. Ann Emerg Med 2007 May; 49(5): 670–7.